Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors

Abstract

These data provide further evidence that prolonged HSP90i exposure improves biologic activity through sustained downregulation of client proteins.